Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: tymeinc.com
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
15-12G - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
POS AM - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
POS AM - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
Fastest customizable press release news feed in the world
-- Combined Company to Trade on Nasdaq Under Ticker "SYRS" ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pu
-- Combined Company to Trade on Nasdaq Under Ticker "SYRS" -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pursuant to which a direct, wholly owned subsidiary of Syros will merge with
BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) ("Tyme" or the "Company"), today announced that independent proxy advisory firms Glass, Lewis & Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") have recommended that Tyme stockholders vote "FOR" the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. ("Syros") and "FOR" all other matters to be voted upon at the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for September 15, 2022 at 11:00 a.m., Eastern Time. ISS and Glass Lewis are leading independent, third-party proxy advisory firms who, among other services, provide pro
Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-dow
BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022. In March the Company announced that its Board of Directors decided to explore potential strategic options to enhance stockholder value, and this process is active and ongoing. The Company plans to provide an update upon completion of this process. Fourth Fiscal Quarter and Full Year 2022 Financial Results As of the quarter ended March 31, 2022, the Company had approximately $84.0 mi
BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value. The Company has engaged Moelis & Company LLC as its financial advisor and Faegre Drinker Biddle & Reath LLP as its legal advisor. On January 26, 2022, TYME announced the discontinuation of a randomized Phase II/III trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus (MPS) for patients with metastatic pancreatic cancer upon learning that the trial
– Industry veteran, Christine D. Baker, joins Board of Directors – Douglas A. Michels appointed Chairman of the Board TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced changes to its Board of Directors. Christine D. Baker Named to Board of Directors The Company is pleased to announce that Christine D. Baker has been appointed to TYME's Board of Directors. Ms. Baker brings over 30 years of experience in the biotech/pharmaceutical industry, with expertise in business development, commercialization, and drug development strategies. She is currently the Chief Business Officer
-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive breast cancer -- -- Poster presentation April 11, 1:30pm ET; abstract available online -- BEDMINSTER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the availability of the poster abstract, "SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer," which was submitted by researchers from Georgetown University. The abstract will be pr
– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing's and other sarcoma types – Pursuing options to diversify the clinical pipeline – Well-capitalized position, with $92.0 million in cash and marketable securities as of December 31, 2021 – Company to host live conference call and webcast today, February 11, at 8:30 AM ET TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emer
TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors s
Live Leadership Updates
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Tornout will provide leadership and direction for all medical and related preclinical programs in development. He will be replacing Dr. Giuseppe Del Priore. “On behalf of the board of directors, we truly appreciate Giuseppe’s many contributions towards advancing our programs and we wish him continued success in his future endeavors,” said Richie Cunningham, TYME’s CEO. Dr. Van Tornout brings
This live feed shows all institutional transactions in real time.
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
Live finance-specific insights
Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-dow
– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing's and other sarcoma types – Pursuing options to diversify the clinical pipeline – Well-capitalized position, with $92.0 million in cash and marketable securities as of December 31, 2021 – Company to host live conference call and webcast today, February 11, at 8:30 AM ET TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emer
TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors s
– First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – – PanCAN Precision Promise trial to add five new sites in early 2022 – – Commenced preclinical initiative with Evotec, a global leader in drug development, to evaluate the potential of expanding our SM-88 platform to other indications – – Maintained a well-capitalized position, with $96.6 million in cash and marketable securities as of September 30 – – Company to host live conference call and webcast today, November 8, 2021, at 8:30 AM ET – TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME),
Company to report its second quarter fiscal 2022 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its second quarter 2022 financial results on Monday, November 8, 2021 at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Monday, November 8, 2021 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 5953454 The webcast will be accessible
– Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings – - Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus ("MPS") in metastatic HR+/HER2- breast cancer, with Georgetown University – - Granted U.S. patent claims covering use of tyrosine-based drug delivery method to treat cancer - –Appointed acting Chief Medical Officer Dr. Jan M. Van Tornout, and Chief Financial Officer, Frank Porfido - – Well-capitalized position, with $101.5 million in cash and marketable securities as of Q1 FY2022 - – Company to host liv
Company to report its first quarter fiscal 2022 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its first quarter 2022 financial results on Tuesday, August 10, 2021 at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Tuesday, August 10, 2021 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 4276767 The webcast will b